Excision Repair Cross-Complementing Rodent Repair Group 2 (ERCC2) plays an important role in DNA repair by eliminating bulky DNA adducts produced by platinum agents during the nucleotide excision repair pathway. Several studies have associated polymorphisms in ERCC2 with response to platinum therapy, lung cancer risk, and DNA repair capacity. This study examined ERCC2 polymorphisms and haplotype structure across 18.9 kb in 95 European, 95 African, and 95 Asian individuals. Single-nucleotide polymorphisms (SNPs) (ERCC2 À9164 A4T, À1989 A4G, À516 G4A, 468
INTRODUCTION
Excision Repair Cross-Complementing Rodent Repair Group 2 (ERCC2, OMIM#: 126340) is located on human chromosome 19q13.2-q13.3, contains 23 exons, and spans a genomic distance of 18.9 kb.
1 ERCC2 encodes an ATP-dependent helicase that is a component of the transcription factor complex TFIIH, 2 which participates in both nucleotide excision repair (NER) and basal transcription. 3 TFIIH is involved in the initiation of RNA Polymerase II transcription through mediation of strand separation around lesions for DNA repair. 4 ERCC2 plays an important role in DNA repair by eliminating bulky DNA adducts produced by environmental toxins and xenobiotics through the NER pathway. 2 Inter-and intrastrand cytotoxic, helix-deforming DNA adducts produced by platinum agents can inhibit cellular replication. 5 Damaged DNA fragments containing between 24 and 32 nucleotides may be excised through incisions made in NER. 4, 6, 7 Polymorphisms in ERCC2 may have a profound effect on DNA repair, and can result in xeroderma pigmentosum, trichothiodystrophy, or Cockayne's syndrome. 1, [8] [9] [10] Several studies have also associated polymorphisms in ERCC2 with response to platinum therapy, lung cancer risk, and DNA repair capacity. chemotherapy regimens available to treat advanced colorectal cancer. The introduction of oxaliplatin has improved response rate, duration of progression-free survival, and overall survival in patients with colorectal cancer, compared with other commonly available cytotoxic agents. However, this therapy only benefits 40-60% of patients.
14,15 A previous study found associations between the ERCC2 polymorphism 2251 T4G [Lys751Gln] with platinum-based chemotherapy response.
2 ERCC2 Lys751Gln was analyzed in 73 patients with metastatic colorectal cancer, who were treated with 5-FU and oxaliplatin. Only 10% of patients with the Gln/Gln genotype responded to the platinum therapy, while 24% of patients with Lys/Lys genotype responded (P ¼ 0.015). 2 In addition, the C4A transversion at nucleotide 468 [Arg156Arg] and 934 G4A [Asp312Asn] were examined; however, there was no association with response. ERCC2 Lys751Gln was thought to be in linkage disequilibrium with the Arg156Arg and Asp312Asn polymorphisms. 2 There has also been an association between polymorphisms in ERCC2 and risk of lung cancer in Asians. Out of 1006 primary lung cancer patients and 1020 population controls of Asian ethnicity, patients homozygous variant for the ERCC2 codon 751 polymorphism had an increased risk of lung cancer (OR ¼ 2.71). 3 Patients homozygous variant for ERCC2 codon 312 also had an increased risk of lung cancer (OR ¼ 10.33). 3 Conversely, a study conducted using 315 patients with primary lung cancer and 315 population controls in Finland found no direct association between lung cancer risk and polymorphisms in DNA repair genes.
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Another study consisting of 341 European lung cancer patients found a decrease in DNA repair capacity for patients with both variant alleles for Lys751Gln and Asp312Asn compared to their controls (Po0.001). 12 There are very little data on the polymorphisms and haplotypes of ERCC2 in different populations. A closer examination of ERCC2 is necessary, especially in the promoter region, in order to determine its functional relevance. This study determined ERCC2 frequencies in multiple populations and identified population specific haplotypes for ERCC2.
RESULTS

Genotyping
Data mining of ERCC2, using PolyMAPr and Promolign, identified four single-nucleotide polymorphisms (SNPs) within the coding region (including the previously published ERCC2 2251 T4G [Lys751Gln]), and three SNPs within the 5 0 UTR/flanking region 10 kb upstream of the transcription start site. SNPs 2251 and 468 were specifically selected based on previous published data on their putative association with platinum response.
2 ERCC2 À9164 and À516 were of particular interest because they were identified as being in regions of homology between mouse and human. Of the seven SNPs, the synonymous cSNP at codon 579 (Val) could not be confirmed in our populations. The remaining six SNPs demonstrated distinct differences in Figure 2 display the haplotypes that were inferred from the genotyping data in this study. In the European population, 77% of the genomic structure consisted of haplotypes 1, 2, or 3. In the African population, Haplotype 5 (54%) was dominant, but only at a low frequency (5%) in Europeans, and was absent in the Asian group. In the Asian population, Haplotypes 1 and 2 represent 89% of all haplotypes. The predicted ERCC2 haplotype evolutionary path for the three populations is shown in Figure 3 . SNPs in the 5 0 UTR or 5 0 flanking region are predicted to be the cause of the main divergence between the populations, whereas generally cSNPs 
ERCC2 polymorphisms
CR King et al demonstrate differences in ERCC2 haplotypes within the populations. In an attempt to reduce the required genotyping burden to infer haplotype, the haplotype tag SNPs (htSNPs) were computationally defined. Evaluation of 9164 A4T, À1989 A4G, 2133 C4T, and 2251 T4G will clearly define ERCC2 haplotype in the vast majority of subjects evaluated (82-91%).
Loss of Heterozygosity (LOH)
In the 52 paired colon samples, 94 heterozygous loci were observed. Of these 94 loci, the genotypes differed between normal and tumor from the same individual on one occasion (1/94; 1%). This low frequency of variation between germline and tumor cells indicates that LOH of the ERCC2-containing region on chromosome 19 is not a significant event in colorectal cancer. Consequently, germ-line ERCC2 polymorphisms are a useful predictor of tumour genotypes. 
RNA Expression
DISCUSSION
Many studies have examined ERCC2 and its association with response to platinum therapy, lung cancer risk, and DNA repair capacity. 2, 3, 11, 12 Due to its importance in DNA damage control, variability in ERCC2 expression and function may have a serious impact. In this study, a total of seven coding region or promoter SNPs were identified using public resources, and only one (ERCC2 1737 C4T [Val579Val]) could not be confirmed in our populations. This may be present in other populations or may represent a rare allele. ERCC2 -9164 A4T is particularly interesting because it lies in a region of the human genome with high homology to the mouse ERCC2 gene. In addition, ERCC2 À9164 A4T was a htSNP in all three populations. Regions conserved between species are likely to contain functionally important domains.
This study emphasizes the ethnic differences of variant allele frequencies between the populations. ERCC2 468 C4A was linked to both 2251 T4G and 2133 C4T in the European population, but not in the African and Asian populations (Table 1) . Differences in associations found between ERCC2 SNPs in one population, but not confirmed in another, could potentially be explained by variability in 
*htSNP in all populations; **htSNP in the European population; ***htSNP in the African population. 3 another found no association in the Finnish population. 11 This SNP is rarely found in Asian subjects (allele frequency ¼ 0.09) and there is little overlap in the haplotypes containing the G allele between Asian and European subjects.
The interpopulation variability in haplotype structure highlights the importance of assessing multiple populations for both genotype and haplotype markers. The predicted haplotype evolutionary path (Figure 3) demonstrates that, while cSNPs identify differences in ERCC2 haplotypes within populations, 5 0 UTR and 5 0 flanking region SNPs identify differences between populations. This implies that coding region polymorphisms in ERCC2 are a more recent evolutionary event. A comprehensive analysis of polymorphisms and linkage blocks across the entire gene, including intronic regions, would help to elucidate the evolutionary network for ERCC2 variation.
This study focused on coding and putative promoter region SNPs found in public databases, based on the likelihood of variations in these regions having functional significance. Polymorphisms in coding regions, especially with amino-acid changes, may affect protein expression, structure and/or function. 16 Polymorphisms located in the promoter region may have an effect on RNA expression. 17, 18 Although there was no association between RNA expression and the ERCC2 polymorphisms in this study, the focus was on RNA expression. A more in-depth analysis of ERCC2 could reveal other significant ERCC2 polymorphisms, which can then be analyzed in future function and association studies.
MATERIALS AND METHODS
Data Mining
Human ERCC2 genomic sequence was annotated to confirm splice site junctions using UCSC Golden Path Human Genome Browser (http://genome.ucsc.edu/cgi-bin/ hgGateway). Once annotated, polymorphisms were then mapped using Polymorphism Mining and Annotation Programs (PolyMAPr). 19 PolyMAPr is a program designed to improve the efficiency of database mining and polymorphism annotation by mapping gene sequences from local and web-based databases, including dbSNP (http://www.ncbi.nlm.nih.gov/SNP/index.html), CGAP-GAI (http://lpgws.nci.nih.gov/perl/snpbr), and JSNP (http://gdb. jst.go.jp/HOWDY/). PolyMAPr is available on request, free of charge to academic users, by emailing the corresponding author. SNPs were then selected from the coding region. In addition, SNPs in the putative promoter region were selected using Promolign (http://polly.wustl.edu/promolign/main.html). 20 Promolign is designed to locate human and mouse orthologous regions, define associated SNPs, and describe putative transcription factor-binding sites in the 10 kb upstream of the transcriptional start site of human genes. Table 2 .
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Population and Patient Samples
Genomic DNA was extracted from whole blood of 95 European (52% males and 48% females of European descent from the United States) and 95 African (36% males and 64% females from Ghana, Africa) healthy blood donors, as described previously. 21, 22 Genomic DNA from a representative Asian population was obtained from the Coriell Institute (http://coriell.umdnj.edu/). DNA and RNA samples from paired tumor and normal colon tissue from 52 Dukes' C colorectal cancer patients (29 males; 23 females, age range 33-102 years; median 68 years) were prepared by the Siteman Cancer Center Tissue Precurement Core. Written informed consent was obtained from all patients to bank tumor tissue and to perform genomic analysis. This study was approved by the Washington University Human Subjects Committee.
Genotyping PCR primers were designed using Primer Express Version 2.0 (ABI, Foster City, CA, USA) and Pyrosequencing Primer SNP Design Version 1.01 software (http://www.Pyrosequencing. com). PCR was carried out using 1-5 ng genomic DNA, 0.6 nmol each of forward and reverse oligonucleotide PCR primers (one of which is biotinylated) (Integrated DNA Technologies, Coralville, IA, USA) and 1X AmpliTaq Gold PCR Master Mix (Applied Biosystems, CA, USA), containing 255 U (0.05 U/ml) AmpliTaq Gold DNA polymerase, Gene Amp PCR Gold buffer (30 mmol/L Tris hydrogen chloride, 100 mmol/L potassium chloride, pH 8.05), 400 mM dNTP, and 5 mmol/L magnesium chloride. Primer details and PCR conditions are described in Table 3 . Pyrosequencing was carried out as described, 23 using an internal primer diluted in 1 Â annealing buffer (20 mmol/L Tris-acetate, 2 mmol/L Mg Ac2), 2 Â binding wash buffer II pH 7.6 (10 mmol/L TrisHCl, 2 M NaCl, 1 mmol/L EDTA, 0.1% Tween20), 2 ml per reaction well Streptavidin Sepharose Beads (Amersham Biosciences, Uppsala, Sweeden), 0.2 M NaOH, 70% ethanol, and a PSQ HS96A SNP reagent kit (Pyrosequencing AB, Uppsala, Sweden). Samples were analyzed on a PSQ HS96A instrument with pyrosequencing software (Pyrosequencing AB, Uppsala, Sweeden).
Quantitative Real-time RT-PCR Tissue total RNA from the paired tumor and normal colon tissue was reverse-transcribed into cDNA using Superscript IIt reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Real-time PCR was carried out in a 10-ml reaction mix containing 2 ml of cDNA (10 ng/ml), 5 ml of 2Â TaqMan universal PCR master mix (Applied Biosystem, Foster City, CA, USA), and 3 ml of primer and probe mix (400 nM each forward and reverse primers and 200 nM TaqMan probe (IDT, Coralville, IA, USA)). Primer sequences for ERCC2 are as follows: forward 5 0 -TTGGCGTCCCCTACGTCTAC-3 0 , reverse 5 0 -CTGGTCCCGCAGGTATTCC-3 0 , and probe 5 0 -CACAGAGCCGCATTCTCAAGGCG-3 0 . All real-time PCR assays were performed in triplicate on an ABI PRISM 7700 Sequence Detector System (ABI, Foster City, CA, USA) with the following program: 501C for 2 min to activate uracil Table 3 N-glycosylase enzyme, 951C for 10 min to denature uracil n-glycosylase and activate DNA polymerase, 40 cycles at 951C for 20 s, and at 601C for 1 min. The sequence detection program calculates a threshold cycle number (C T ) at which the reporter fluorescence generated by cleavage of the probe is statistically greater than that of the background signal. 24 In this study, relative expression level was calculated using the modified comparative C T method as described previously; 25 that is, the relative expression level of an individual target gene was normalized to the reference gene (amyloid b precursor protein) and to the RNA sample, with the maximum C T value in the target gene. 24, 26 The formula for relative gene expression was utilized as described previously. 25, 26 Computational Analysis Genotype-frequency analysis of Hardy-Weinberg equilibrium, linkage disequilibrium (|D 0 |), and haplotype analysis were carried out using the Polymorphism and Haplotype Analysis SuitE (http://ilya.wustl.edu/~pgrn/). 27 This program tests for Hardy-Weinberg equilibrium as well as determines allele and genotype counts and linkage disequilibrium. htSNPs were also determined using SNPtagger (http://www.well.ox.ac.uk/~xiayi/haplotype/index.html).
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NETW4101 was used to construct the haplotype tree (http:// www.fluxus-engineering.com).
Statistical Analysis
RNA expression statistical analyses were performed using STATISTICA from StatSoft, Inc. (Tulsa, OK, USA). Significance of the difference of relative expression level between paired tumor and normal samples was evaluated by the Wilcoxon matched pairs test. The significance level was set at Po0.05. Correlation between variables was measured with Spearman rank correlation.
